ArticleFrontiers in immunology2021
Designing Multi-Antigen Vaccines Against
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- OmpA virulence factor, a promising conserved vaccine candidate against Acinetobacter baumannii, could trigger autoreactive immune responses in susceptible population.BMC immunology · 2025Article
- Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii.Scientific reports · 2025Article
- Multidrug resistantCurrent research in microbial sciences · 2025Review
- Deep Intraclonal Analysis for the Development of Vaccines against Drug-ResistantInternational journal of molecular sciences · 2024Article
- Artificial Intelligence Application for Anti-tumor Drug Synergy Prediction.Current medicinal chemistry · 2024Review
- TonB-Dependent Receptor Protein Displayed on Spores ofVaccines · 2023Article
- Protective Capacity of Monoclonal Antibodies against Acinetobacter baumannii K9 Capsular Polysaccharide.Microbiology spectrum · 2023Article
- Editorial: Recent advances in the development of vaccines againstFrontiers in immunology · 2023Article
- Non-antibiotic prevention and treatment againstFrontiers in microbiology · 2023Review
- Structural diversity amongFrontiers in microbiology · 2023Article
- Review
- Looking at COVID-19 from a Systems Biology Perspective.Biomolecules · 2022Review
- Integrativesubtractive proteomics, immunoinformatics, docking, and simulation approaches reveal candidate vaccine against Sin Nombre orthohantavirus.Frontiers in immunology · 2022Article
- Whole-cell vaccine candidates induce a protective response against virulentFrontiers in immunology · 2022Article
- PromisingFrontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines and monoclonal antibodies are promising approaches for preventing and treating infections caused by multidrug resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.